{
    "nct_id": "NCT03744468",
    "official_title": "Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors",
    "inclusion_criteria": "Has Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1.\n\n* Adequate organ function\n* Phase 1 Dose Escalation + Phase 2 Safety Lead-In: Participants with histologically or cytologically confirmed advanced, metastatic, unresectable solid tumors who have previously received standard systemic therapy or for which treatment is not available, not tolerated or refused.\n* Phase 2 Dose-Expansion: Participants with one of the following histologically or cytologically confirmed solid tumors:\n* For HNSCC participants in cohort 1,4 and 6 (PD-L1 positive):\n\nRecurrent/metastatic head and neck squamous cell cancer of the oral cavity, oropharynx, hypopharynx, and/or larynx whose tumor is not amenable to local therapy with curative intent (ie, surgery or radiation therapy with or without chemotherapy • For NSCLC participants in Cohort 2, 5 and 7 (PD-L1 positive): Locally recurrent Stage IIIB, stage IIIC or Stage IV squamous or non-squamous non-small cell lung cancer\n\n• For RCC participants in Cohort 3: Locally advanced unresectable or metastatic and histologically confirmed renal cell carcinoma with a clear cell histology\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* NSCLC patients with known EGFR mutation, BRAF mutation, ALK fusion, or ROS1 fusion\n* Active leptomeningeal disease or uncontrolled, untreated brain metastasis.\n* Active autoimmune diseases or history of autoimmune diseases that may relapse.\n* Interstitial lung disease, noninfectious pneumonitis or uncontrolled lung diseases\n* Uncontrolled diabetes or significant cardiac issues\n* Infections requiring systemic antibacterial, antifungal, or antiviral therapy\n* History of severe hypersensitivity reactions to other monoclonal antibodies\n* History of HIV infection or untreated chronic hepatitis B or chronic hepatitis B virus carriers\n* Major surgical procedure within 28 days before study drug administration\n* Chemotherapy, radiotherapy, immunotherapy or any investigational therapies within 28 days (PH 2 Safety Lead-In) or 14 days (PH 2 Dose Expansion) or 5 half-lives of (whichever is shorter) of first administration of study drug(s).\n* With infections (including tuberculosis infection, etc) requiring systemic antibacterial, antifungal, or antiviral therapy ≤ 14 days prior to the first dose of study drug(s), or a requirement for chronic prophylactic treatment with antibiotics.\n* Concurrent participation in another therapeutic clinical trial\n* Received prior therapies targeting TIM-3and/or LAG3\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}